Use of oncolytic viruses for the treatment of cancer
AssigneeAmgen Inc.
InventorsJason James DEVOSS, Walter Hans MEISEN, Christine Elaine TINBERG, Keegan S. COOKE, Achim Klaus MOESTA
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of oncolytic viruses (e.g., modified HSV-1 viruses) for the treatment of various types of cancer. In addition, the present invention relates to compositions and kits relating to such uses of oncolytic viruses.
Claims15
1-34. (canceled)
An oncolytic herpes simplex virus,
- wherein said oncolytic herpes simplex virus:
- lacks a functional gene encoding ICP 34.5,
- lacks a functional gene encoding ICP 47, and
- wherein said oncolytic herpes simplex virus contains:
- a nucleic acid sequence encoding Fms-related tyrosine kinase 3 ligand (FLT3L),
- a nucleic acid sequence encoding interleukin-12 (IL12), and
- a nucleic acid encoding a Kozak sequence;
- wherein the nucleic acid sequence encoding FLT3L and the nucleic acid sequence encoding IL12 are both under the control of a cytomegalovirus (CMV) promotor;
- and
- wherein the nucleic acid sequence encoding FLT3L and the nucleic acid sequence encoding IL12 are linked by the polycistronic linker element porcine tescho virus 2a (P2A).
An oncolytic herpes simplex virus, wherein said oncolytic herpes simplex virus is HSV1/ICP34.5−/ICP47−/FLT3L/IL12, wherein said HSV1/ICP34.5−/ICP47−/FLT3L/IL12 comprises a modified HSV-1 derived from strain JS1, wherein the HSV-1 lacks a functional ICP34.5 encoding gene, lacks a functional ICP47 encoding gene, comprises the following inserted into the former sites of the ICP34.5 gene:
- [CMV]-[Kozak]-[FLT3L]-[P2A]-[IL12(p40-GGGGS-No SP-p35)]-[BGHpA].
Dependencies are inferred from the claim text.